Clopidogrel is an antiplatelet agent used to prevent in-stent thrombosis after percutaneous coronary intervention (PCI). Discontinuation of clopidogrel therapy within 1 month of PCI results in in-stent thrombosis in more than 25% of patients and is associated with high mortality.1 Up to 6% of patients will develop a clopidogrel allergy but remain dependent on antiplatelet agents to prevent in-stent thrombosis.2- 4 We report a case of generalized bullous fixed drug eruption associated with clopidogrel and review the recommended management strategies for clopidogrel allergy.
Fett N. Management of Antiplatelet Allergy After Cardiac Stenting. JAMA Dermatol. 2016;152(10):1169-1170. doi:10.1001/jamadermatol.2016.1983